Payment overview · 2025
General Payments
$266.98
13 reported records · 8 companies
Healthcare provider profile · identity verified
Minesh Shah, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CHATHAM, VA · NPI 1518960673
Verified facts
What the public records show
CMS Open Payments records show Minesh Shah, M.D. received $266.98 in general payments during 2025 across 13 reported records.
Lilly USA, LLC accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 348 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.33 | 21.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.10 | 20.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.92 | 17.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.29 | 11.3% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $23.21 | 8.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.84 | 8.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.34 | 6.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.95 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $266.98 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.10 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.92 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.92 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.29 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 236 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
348 | 47 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
236 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1213 | 265 |
| Amlodipine Besylate | Amlodipine Besylate | 1091 | 241 |
| Levothyroxine Sodium | Levothyroxine Sodium | 692 | 127 |
| Omeprazole | Omeprazole | 607 | 150 |
| Losartan Potassium | Losartan Potassium | 561 | 124 |
| Metformin Hcl | Metformin Hcl | 561 | 112 |
| Gabapentin | Gabapentin | 544 | 101 |
| Furosemide | Furosemide | 507 | 120 |
| Lisinopril | Lisinopril | 477 | 102 |
| Eliquis | Apixaban | 394 | 38 |
| Alprazolam | Alprazolam | 383 | 60 |
| Simvastatin | Simvastatin | 378 | 94 |
| Prednisone | Prednisone | 349 | 102 |
| Farxiga | Dapagliflozin Propanediol | 348 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 318 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 317 | 70 |
| Allopurinol | Allopurinol | 270 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 67 |
| Trazodone Hcl | Trazodone Hcl | 252 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 243 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 241 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 241 | 53 |
| Ozempic | Semaglutide | 236 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 224 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 52 |
| Potassium Chloride | Potassium Chloride | 216 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 215 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 214 | 61 |
| Glipizide Er | Glipizide | 214 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 32 |
| Clonazepam | Clonazepam | 202 | 30 |
| Donepezil Hcl | Donepezil Hcl | 201 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 174 | 32 |
| Spironolactone | Spironolactone | 173 | 31 |
| Meloxicam | Meloxicam | 172 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 169 | 34 |
| Tramadol Hcl | Tramadol Hcl | 166 | 36 |
| Carvedilol | Carvedilol | 165 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 159 | 39 |
| Januvia | Sitagliptin Phosphate | 155 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 155 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 153 | 48 |
| Finasteride | Finasteride | 139 | 30 |
| Montelukast Sodium | Montelukast Sodium | 135 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 29 |
| Memantine Hcl | Memantine Hcl | 129 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 126 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 120 | 24 |
| Baclofen | Baclofen | 120 | 44 |
| Atenolol | Atenolol | 118 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 118 | 72 |
| Glipizide | Glipizide | 117 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 116 | 92 |
| Buspirone Hcl | Buspirone Hcl | 112 | 18 |
| Entresto | Sacubitril/Valsartan | 111 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 108 | 29 |
| Famotidine | Famotidine | 104 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 103 | 64 |
| Mirtazapine | Mirtazapine | 101 | 24 |
| Lorazepam | Lorazepam | 97 | 18 |
| Glimepiride | Glimepiride | 90 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | 19 |
| Novolog Flexpen | Insulin Aspart | 87 | 19 |
| Warfarin Sodium | Warfarin Sodium | 85 | 16 |
| Xarelto | Rivaroxaban | 84 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 82 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 78 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 17 |
| Diazepam | Diazepam | 75 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 75 | 15 |
| Topiramate | Topiramate | 73 | 13 |
| Fluconazole | Fluconazole | 72 | 35 |
| Lovastatin | Lovastatin | 70 | 18 |
| Ibuprofen | Ibuprofen | 69 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 66 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 64 | 14 |
| Ezetimibe | Ezetimibe | 64 | 11 |
| Valsartan | Valsartan | 64 | 19 |
| Bupropion Xl | Bupropion Hcl | 62 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 46 |
| Lamotrigine | Lamotrigine | 62 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 60 | 16 |
| Levetiracetam | Levetiracetam | 59 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 59 | 16 |
| Azithromycin | Azithromycin | 57 | 48 |
| Pregabalin | Pregabalin | 57 | 11 |
| Amoxicillin | Amoxicillin | 55 | 40 |
| Aripiprazole | Aripiprazole | 54 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 53 | 16 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 52 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 50 | 11 |
| Cephalexin | Cephalexin | 48 | 37 |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Tradjenta | Linagliptin | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Latanoprost | Latanoprost | 45 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 44 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Torsemide | Torsemide | 41 | suppressed |
| Levemir Flexpen | Insulin Detemir | 38 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 37 | 37 |
| Metolazone | Metolazone | 37 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Nystatin | Nystatin | 35 | 25 |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Metronidazole | Metronidazole | 32 | 19 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Travoprost | Travoprost | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Repatha Syringe | Evolocumab | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 13 |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | 16 |
| Rhopressa | Netarsudil Mesylate | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Veltassa | Patiromer Calcium Sorbitex | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Restasis Multidose | Cyclosporine | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $266.98 · 13 records | Lilly USA, LLC | AUSTEDO XR, BREZTRI, CAPLYTA, Fluad, Flucelvax, MOUNJARO, OTEZLA, Ozempic, REPATHA, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error